Key Highlights

  • Perrigo shares closed at $14.69 today, up 6.11%.
  • The rally comes as investors respond to a fresh wave of bullish analyst sentiment, including an upgrade from a research firm and a separate analysis suggesting shares are undervalued relative to fair value.
  • The rebound extends momentum from the company's August 5 Earnings beat, in which it posted $0.50 in adjusted Earnings Per Share versus a $0.39 consensus estimate.
  • The stock's elevated 7.8% Dividend Yield continues to draw income-focused investors amid the recent volatility.

Bullish Analyst Sentiment Fuels the Rebound

Perrigo (NYSE:PRGO) shares closed sharply higher today, rebounding from Wednesday's 3.3% decline, as investors responded to a fresh wave of bullish analyst sentiment. A research firm upgraded the stock last week, and a separate Valuation Analysis flagged the shares as undervalued relative to fair-value estimates following the recent pullback, adding to renewed buying interest.

Earnings Beat Continues to Support the Story

The rally also extends momentum from Perrigo's August 5 earnings beat, in which the company posted adjusted earnings per share of $0.50 versus a $0.39 consensus estimate, reinforcing improving fundamentals even as the broader healthcare sector has lagged the market this year. Analysts maintain a consensus Hold rating with a $19.33 average price target, and the stock's elevated 7.8% dividend yield continues to draw income-focused investors amid the volatility.

A Leading Global Provider of Over-the-Counter Health Products

Perrigo is a leading global provider of over-the-counter health and wellness products headquartered in Dublin, Ireland, operating through its Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers a broad portfolio spanning upper respiratory, digestive health, pain and sleep-aid, oral care, nutrition, women's health, skin care and vitamins and supplements categories, marketed under well-known brands including Compeed, Mederma, Opill, Solpadeine and Remembrand, and sells its products through retail drug chains, supermarkets, mass merchandisers and pharmacies across North America, Europe and other international markets.